IND-SWIFT LABORATORIES LTD. - 532305 - Receipt Of IDMA N.I. Gandhi - Chief Mentor Award By Sh. Navrattan Munjal, Chairman & Managing Director
Please refer enclosed pdf26-02-2024
26-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Disclosure Under Regulation 30(5)
Disclosure under regulation 30(5)12-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Compliances-Reg. 54 - Asset Cover details
Security Cover details as at 31-12-202312-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Results- Financial Results For The Quarter Ended December 31, 2023
Financial Results for the quarter ended 31st December, 2023.12-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 12Th February, 2024
Outcome of the Board Meeting.12-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd08-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Disclosure Under Regulation 10(5) Of SEBI (SAST) Regulations, 2011
Disclosure under Regulation 10(5) of SEBI (SAST) Regulations, 2011, as received from M/s. Essix Biosciences Limited07-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD
Intimation of payment of interest under Regulation 5701-02-2024
IND-SWIFT LABORATORIES LTD. - 532305 - Board Meeting Intimation for Board Meeting Intimation For Notice Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR), Regulations, 2015
IND-SWIFT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and approve IND-SWIFT LABORATORIES LTD. has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia, to consider and approve unaudited standalone and consolidated financial statements for the quarter and nine months ended on December 31, 2023.29-01-2024